Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial

Basit Öğe Kaydı
dc.authorscopusidİrfan Çiçin / 8922379100
dc.authorwosidİrfan Çiçin / JQU-1347-2023
dc.contributor.authorCamidge, D. Ross
dc.contributor.authorBar, Jair
dc.contributor.authorHorinouchi, Hidehito
dc.contributor.authorGoldman, Jonathan
dc.contributor.authorMoiseenko, Fedor
dc.contributor.authorFilippova, Elena
dc.contributor.authorÇiçin, İrfan
dc.date.accessioned2025-04-18T10:09:59Z
dc.date.available2025-04-18T10:09:59Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractPURPOSE Telisotuzumab vedotin (Teliso-V) is a c-Met-directed antibody-drug conjugate with a monomethyl auristatin E cytotoxic payload. The phase II LUMINOSITY trial (ClinicalTrials.gov identifier: NCT03539536) aimed to identify the optimal c-Met protein-overexpressing non-small cell lung cancer (NSCLC) population for treatment with Teliso-V (stage I) and expand the selected group for efficacy evaluation (stage II). Stage II enrolled patients with nonsquamous epidermal growth factor receptor (EGFR)-wildtype NSCLC. METHODS Eligible patients had locally advanced/metastatic c-Met protein-overexpressing NSCLC and <= 2 previous lines of therapy (including <= 1 line of systemic chemotherapy). c-Met protein overexpression in nonsquamous EGFR-wildtype NSCLC was defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25%-<50%]). Teliso-V was administered at 1.9 mg/kg once every 2 weeks. The primary end point was overall response rate (ORR) by independent central review. RESULTS In total, 172 patients with nonsquamous EGFR-wildtype NSCLC received Teliso-V in stages I and II. ORR was 28.6% (95% CI, 21.7 to 36.2; c-Met high, 34.6% [95% CI, 24.2 to 46.2]; c-Met intermediate, 22.9% [95% CI, 14.4 to 33.4]). The median duration of response was 8.3 months (95% CI, 5.6 to 11.3; c-Met high, 9.0 [95% CI, 4.2 to 13.0]; c-Met intermediate: 7.2 [95% CI, 5.3 to 11.5]). The median overall survival was 14.5 months (95% CI, 9.9 to 16.6; c-Met high, 14.6 [95% CI, 9.2 to 25.6]; c-Met intermediate, 14.2 [95% CI, 9.6 to 16.6]). The median progression-free survival was 5.7 months (95% CI, 4.6 to 6.9; c-Met high, 5.5 [95% CI, 4.1 to 8.3]; c-Met intermediate: 6.0 [95% CI, 4.5 to 8.1]). Most common any-grade treatment-related adverse events (AEs) were peripheral sensory neuropathy (30%), peripheral edema (16%), and fatigue (14%); the most common grade >= 3 AE was peripheral sensory neuropathy (7%). CONCLUSION Teliso-V was associated with durable responses in c-Met protein-overexpressing nonsquamous EGFR-wildtype NSCLC, especially in those with high c-Met. AEs were generally manageable.
dc.description.sponsorshipAbbVie
dc.identifier.citationCamidge, D. R., Bar, J., Horinouchi, H., Goldman, J., Moiseenko, F., Filippova, E., ... & Lu, S. (2024). Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial. Journal of Clinical Oncology, JCO-24.
dc.identifier.doi10.1200/JCO.24.00720
dc.identifier.endpage3011
dc.identifier.issn0732183X
dc.identifier.issue25
dc.identifier.pmid38843488
dc.identifier.scopus2-s2.0-85201115179
dc.identifier.scopusqualityQ1
dc.identifier.startpage3000
dc.identifier.urihttp://dx.doi.org/10.1200/JCO.24.00720
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6972
dc.identifier.volume42
dc.identifier.wosWOS:001300322800012
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÇiçin, İrfan
dc.institutionauthoridİrfan Çiçin / 0000-0002-7584-3868
dc.language.isoen
dc.publisherLippincott williams and wilkins
dc.relation.ispartofJournal of clinical oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleTelisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
camidge-et-al-2024-telisotuzumab-vedotin-monotherapy-in-patients-with-previously-treated-c-met-protein-overexpressing.pdf
Boyut:
1.21 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu